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Sepsis is a life-threatening syndrome characterized by a dysregulated host response to an infection result-
ing in multiple organ dysfunctions. Early diagnosis and management of sepsis is key to improve patient
outcome but remains challenging. Despite extensive research, only few biomarkers have so far proven
to be helpful in the diagnosis of sepsis. A novel protein biomarker, the pancreatic stone protein (PSP), is
showing great promises. Several lines of evidences suggest that PSP has a higher diagnostic performance
for the identification of sepsis than procalcitonin and C-reactive protein, and a strong prognostic value
to predict unfavorable outcome at admission to intensive care unit. This review summarizes the current
knowledge on the molecular mechanisms of PSP function and the clinical evidences available to highlight
the relevance of this protein in the diagnosis and prognosis of sepsis.
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The burden of sepsis & its challenges for its diagnosis & management
Sepsis is a recognized global health problem. It affects over 30 million people worldwide annually and is the largest
killer of children – >5 million each year [1]. Despite considerable progress in the management of organ failures,
sepsis and septic shock, sepsis is still associated with reported mortality rates around 30%, although mortality rates
can be much higher depending on the geographical location and access to healthcare facilities [2]. With >UD$24
billion each year, sepsis represents the first cost of hospitalization in the USA [3]. Sepsis is the number one cause for
readmissions to the hospital [4], and sepsis survivors experience functional deficits and diminished quality of life,
with persistent higher risk for long-term mortality.
In 2016, a task force convened by national societies proposed a new clinical definition of sepsis (‘Sepsis-3
criteria’), in which sepsis is defined as life-threatening organ dysfunctions caused by a dysregulated host response
to infection [5]. This new definition helps in identifying a subset of infected patients at higher risk of death due
to organ damage and integrates the current understanding of the pathophysiological mechanisms of sepsis. The
pathophysiology of sepsis is complex and relies on a combination of factors related to both the microorganism
and the immune response of the host. It most often follows a sequence of events, including a hyperinflammatory
phase, a persistent inflammation phase and, later on, an immunosuppressive and a catabolic phase, both usually
characterized by a multiple organ dysfunction, reactivation of latent viral infections, a higher susceptibility to
nosocomial infections, as well as long-term functional and cognitive declines [6]. Death can occur at any time,
either during the hyperinflammatory response, or as a result of the immunosuppressive condition, the recurrence
of infections and/or multiple organ dysfunction.
The measurement of severity scores, either at admission (APACHE II [acute physiology and chronic health
evaluation] and/or SAPS II [simplified acute physiology score]) or daily during the intensive care unit (ICU) stay
(i.e., sequential [sepsis-related] organ failure assessment [SOFA]) may help assessing the severity of the infection as
well as the extent of organ dysfunction [5]. Increased severity scores are associated with increased mortality [7]. As
no specific treatment exists to treat the dysregulated host response to infection, management of sepsis thus relies
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on prompt control of the source of infection, early administration of an effective antibiotic therapy and intensive
support of organ dysfunction.
Early recognition of sepsis is essential and a major determinant of the disease’s outcome, repeatedly emphasized
by the WHO and the Surviving Sepsis Campaign [8,9]. However, up to now, it has proven to be challenging,
especially because signs and symptoms of sepsis are nonspecific and biomarkers with high sensitivity and specificity
are still lacking despite extensive research.
A large number of biomarkers have been or are currently studied. They are used to detect sepsis, to assess its
severity, to help triaging patients, to predict sepsis outcome or to monitor the response to treatment. It is important
to stress that the evaluation of biomarker performance should not be restricted to the assessment of its sensitivity,
specificity or accuracy, but should also take into account its cost-effectiveness, its usability, availability and the
total turnaround time. In the context of sepsis, point-of-care testing (POCT) is appealing, as it might provide
clinicians with a rapid and readily available diagnostic value. Of note, the information obtained from biomarkers
must be adapted to the clinical situation and/or the setting of the patient (i.e., ICU, intermediate care, Emergency
Department [ED]).
Today, only few biomarkers are routinely used at the bedside of patients with suspect of sepsis: C-reactive
protein (CRP) and procalcitonin (PCT). CRP is an acute-phase protein mostly secreted by the liver and whose
plasma concentration increases rapidly upon stimulation by proinflammatory cytokines, such as IL-6. Discovered
back in the 1930s [10], CRP is a nonspecific marker of inflammation: its blood concentration rises whenever an
inflammatory process is present, such as in the case of trauma, surgery, bacterial, viral and fungal infection [11,12].
Immunoassays measuring CRP concentration are available since decades, relaying on several techniques such as
ELISA, immunoturbidimetry, nephelometry and rapid immunodiffusion. Nowadays, CRP is measured in clinical
laboratory at low cost and, thanks to its high plasma concentration (in the hundreds of milligrams per liter in
healthy adults), most assays provide results in a relatively short time. Although the low specificity of CRP for sepsis
and the absence of bedside measurement are major drawbacks, CRP is still widely used for both the diagnosis of
sepsis and to monitor critically ill patient’s response to treatment (reviewed in [12]).
PCT is a peptide precursor of the hormone calcitonin and is physiologically secreted by the thyroid gland. PCT
is not detectable in healthy individuals and its level rises within hours in response to proinflammatory stimuli
especially when of bacterial origin (PCT production is attenuated by IFN-γ primarily secreted in response to viral
infection) [13,14]. Major surgery, severe trauma, severe burns, prolonged cardiogenic shock, fungal and malarial
infections may rise PCT as well, and as with any other biomarkers, interpretation of PCT levels thus requires
careful assessment of the patient’s clinical condition [13]. The clinical utility of single or repeated PCT measurement
has been extensively studied in various clinical setting such as primary cares, ED and ICU. Several clinical scenarios,
from diagnosis of bacterial infection to assessment of disease severity, were evaluated. In most of the cases, PCT
sensitivity and specificity were higher than that of CRP. PCT is also used as a prognostic marker of mortality in
ICU [15] and to monitor response to treatment, and especially to guide de-escalation of antibiotic therapy. Indeed,
the US FDA approved in 2017 the use of PCT for guiding antibiotic therapy in patients with acute respiratory
infections [16]. Several reviews and meta-analyses summarizing the most recent findings are available elsewhere [13,17].
PCT is nowadays measured in clinical laboratories by immunoassay techniques; it is relatively costly, especially
when compared with CRP. No technique is currently available for real-time bedside usage.
Other biomarkers, such as soluble CD25 and middle region of pro-adrenomedullin are currently evaluated
in various clinical situations, including the diagnosis of sepsis, the monitoring of response to treatment, the
diagnosis and prediction of organ dysfunction or the evaluation of sepsis and septic shock severity, and are reviewed
elsewhere [18]. One emerging biomarker is attracting special attention: PSP, for pancreatic stone protein, shows
promise as it is characterized by a higher accuracy in the diagnosis and prognosis of sepsis compared with CRP and
PCT (Table 1).
The pancreatic stone protein: structure, function & its role in sepsis
Originally, lithostathine and regenerating protein 1 (Reg I) have been discovered and described by different groups
working on pancreatitis and diabetes. Later on, both proteins have been proven to be identical and were renamed
PSP, for pancreatic stone protein [19,20]. PSP is encoded by a single transcript of the reg gene, resulting in a
144-amino acid length glycoprotein. This form is secreted into the duodenum along the same secretory pathway
as the exocrine enzymes. Trypsin hydrolysis generates a polypeptide of 133 amino acids. Three disulfide bonds
have been characterized and the protein is O-linked glycosylated on threonine in position 27. The functional
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Table 1. Comparison of sepsis host protein biomarker characteristics compared with pancreatic stone protein.
Protein
biomarker
Sensitivity to
detect
infection
Specificity to
detect
infection
Time window
of expression
upon infection
Assessment of
the severity of
sepsis (organ
dysfunction)
Prognostic
factor
Used for
antibiotic
guidance
Bedside
availability
Time from
draw to
results
delivered to
clinicians
Regulatory
status
PSP ++++ ++++ Days ++++ ++++ N.D Yes 5 min CE mark
CRP ++++ + Days +++ + ++ Yes 60 min CE mark, US FDA
cleared
PCT ++++ +++ Days ++ ++ +++ Yes 60 min CE mark, US FDA
cleared
IL-6 ++++ ++ Hours ++++ +++ - Yes 60 min CE mark
The relative performance of each biomarker’s parameter has been evaluated semiquantitatively on a scale going from ‘-’, interpreted as ‘not effective’, to ‘++++’, interpreted as ‘very
effective’, based on published literature and the author’s experience with these biomarkers. Time window of expression upon infection relates to the entire cycle of expression and
clearance of the marker.
CE: ‘Conformite´ Europe´enne’; CRP: C-reactive protein; N.D: Not determined; PCT: Procalcitonin; PSP: Pancreatic stone protein.
roles of this protein have not been clearly elucidated, although structural homologies have been characterized to
date: PSP is a globular polypeptide, which adopts the overall fold described for C-type lectins [21], which are
calcium-dependent glycan-binding proteins known to have a diverse range of functions, including adhesion and
signaling receptors in homeostasis and innate immunity, and are crucial in inflammatory responses and leukocyte
and platelet trafficking [22].
The first function described for PSP was the inhibition of the growth and nucleation of calcium carbonate crystals
in the pancreatic juice. Pancreatic juice is indeed characterized by high concentrations of calcium and carbonate
ions, which can form pancreatic stones and calcium deposits in the pancreas, as in the case of chronic pancreatitis.
As subsequent functional studies have brought conflicting results, it is nowadays a matter of debate whether PSP
really plays a role in this function (discussed in [23]).
PSP has also been associated with pathological changes occurring in the pancreas during pancreatic inflamma-
tion [24] and, upon tryptic cleavage, with a calcium- and pH-dependent bacterial binding to proteoglycan [25].
PSP levels were shown to be slightly higher in patients with Type-2 diabetes mellitus compared with healthy
individuals [26]. This level is even significantly higher in the subset of patients with diabetic kidney disease, a major
complication of diabetes, and an important cause of end-stage renal disease [27].
A pivotal observation was made serendipitously in rat experiments by the group of Rolf Graf in which PSP was
found to be an indicator of systemic stress [28]. This observation was then clinically confirmed in a cohort of trauma
patients, in which serum PSP rises early after trauma for those patients that later develop infection and sepsis [29].
Reding et al. further showed that the pancreas senses remote organ damage and systemic stress and responds by
secreting PSP, particularly when associated with septic complications [30].
Interestingly, incubation of whole blood from healthy volunteers in presence of recombinant PSP results in a
dose-dependent increase of CD11b (a mediator of inflammation) and a decrease of CD62L (a transmembrane
glycoprotein, which rapidly sheds from the cell surface upon activation) on polymorphonuclear neutrophil [29].
Yet it remains uncertain whether there is a direct interaction with a membrane-bound receptor as binding of PSP
required a high concentration. This indicates that PSP might require a binding partner that subsequently induces
activation of signaling pathways participating in the early events of the host response to pathogens.
Preclinical data showing that PSP might activate polymorphonuclear neutrophil, promote bacterial aggregation,
being involved in the host response to pathogens via its C-type lectin domain, prompted its identification as
potential biomarker for sepsis. Moreover, the observation that PSP level rose in response to septic insults in mice
and rats encouraged its clinical evaluation as biomarker of sepsis in various settings and conditions.
Diagnostic & prognostic performance of PSP in sepsis
PSP has been studied and compared with other biomarkers in various settings of infections and sepsis, both as
a diagnostic marker of infection and/or sepsis, or a prognostic marker of disease outcome (Table 2). All studies
available at the time of preparation of this review have been done using the former Sepsis-2 criteria. It is likely (and
desired) that ongoing and future studies will be done following the Sepsis-3 criteria.
In 12 out of 13 studies among various clinical settings (ED, ICU, surgical, nonsurgical adult and children), PSP
proved to be more accurate, with a higher sensitivity, specificity, positive and negative predictive values than CRP,
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Table 2. Summary of clinical evidences pancreatic stone protein for diagnosis of infection and sepsis.
Purpose of the study Study population, characteristics Results, main measurements Conclusion Ref.
Physiological values
PSP reference values in healthy
subjects
397 healthy subjects PSP value (median [IQR]; ng/ml)
32 wGA: 2.6 (2.0–4.3),
32 wGA to 36 wGA: 4.5 (3.5–8.4),
37 wGA to 39 wGA: 6.3 (4.0–10.2),
40 wGA to 1 year: 8.4 (5.9–12.5),
61 children (up to 16 year): 16.1 (12.0–20.1),
61 adults: 10.8 (7.6–12.5)
PSP age-specific normal values,
which may be used to define cutoffs
for future trials. There is an
age-dependent increase of PSP from
birth to childhood
[31]
PSP value in adults
PSP level in post-traumatic
patients (serial measurement of
PSP)
83 multiple trauma patients,
18 no infection,
32 local infections,
33 sepsis,
38 healthy control
PSP (median [IQR] in ng/ml)
Healthy volunteers: 10.4 (7.5–12.3) ng/ml;
No infection:
Initial PSP: 10.5 (7.4–15.2),
Maximal PSP: 22.8;
Local infection
Initial PSP: 10.9 (5.1–14.8),
Maximal: 111.4;
Sepsis:
Initial: 10.6 (6.9–16.3),
Maximal: 146.4
PSP is upregulated in blood after
trauma, and the PSP level is related
to the severity of inflammation. PSP
level mirrored the onset and peak of
sepsis
[29]
Diagnosis of sepsis in patients
admitted to ICU or high
dependency care units (PSP
measured within 6 h of
admission)
219 unselected patients Accuracy (AUROCC) for sepsis versus no
sepsis with organ failures:
IL-6 (200 pg/ml) = 0.82 (95% CI:
0.74–0.89),
IL-8 (80 pg/ml) = 0.76 (95% CI: 0.68–0.84),
IL-1b (1.0 pg/ml) = 0.77 (95% CI:
0.69–0.85),
HBP (50 ng/ml) = 0.58 (95% CI: 0.48–0.68),
TNFa sCD25 (2.5 ng/ml) = 0.87 (95% CI:
0.81–0.93),
PCT (1.0 ng/ml) = 0.84 (95% CI: 0.77–0.91),
PSP (30 ng/ml): AUC 0.91 (95% CI:
0.86–0.96)
PSP outperforms other biomarkers,
including PCT, in patients with
suspected sepsis at the time of
admission to intensive or high
dependency care units
[32]
Prediction of outcome of
complication of postoperative
peritonitis patients
91 postoperative peritonitis
patients admitted to the ICU. PSP
and PCT determined within 3 h
from admission to the ICU
Accuracy (AUROCC) for: organ failure:
WCC = 0.38 (95% CI: 0.27–0.50),
CRP = 0.50 (95% CI: 0.38–0.63),
IL-6 = 0.61 (95% CI: 0.48–0.74),
PCT = 0.73 (95% CI: 0.62–0.83),
PSP = 0.81 (95% CI: 0.71–0.90);
Multiple organ failure:
WCC = 0.47 (95% CI: 0.32–0.57),
CRP = 0.53 (95% CI: 0.40–0.65),
IL-6 = 0.60 (95% CI: 0-49–0.72),
PCT = 0.71 (0.60–0.82),
PSP = 0.75 (95% CI: 0.64–0.85);
Death:
WCC = 0.49 (95% CI: 0.34–0.64),
CRP = 0.48 (95% CI: 0.35–0.62),
IL-6 = 0.64 (95% CI: 0.51–0.76),
PCT = 0.63 (95% CI: 0.63–0.76),
PSP = 0.77 (95% CI: 0.67–0.88)
Among biomarkers, only serum PSP
measured at admission to the
surgical ICU is a reliable marker to
discriminate the severity of
peritonitis and the prediction of
death in the ICU, when compared
with CRP, WCC, IL-6 and PCT
[33]
PSP value after cardiac surgery
and to identify infection and
sepsis (daily measurement of PSP)
120 adult patients post -cardiac
surgery
– 18 infections (3 sepsis)
– Pneumonia (8)
– UTI (3)
–Wound (4)
– Mediastinitis (1)
Accuracy (AUROCC) for predication of
infection on day 1 post surgery:
CRP = 0.66,
WCC = 0.66,
PSP = 0.72;
Day 2 post surgery:
CRP = 0.53,
WCC = 0.64,
PSP = 0.76;
Day 3 post surgery:
CRP = 0.58,
WCC = 0.53,
PSP 0.74
PSP rises in all postcardiac surgery
patients. Levels of PSP at
postoperative days 1–3 has
discriminatory properties for
identifying infection early that is
superior to WCC and CRP
[34]
This table summarized the key clinical findings of studies in which the PSP has been evaluated for different clinical situations on different patient populations. For most studies, PSP
has been compared with other standard or emerging biomarkers.
AUC: Area under the curve; AUROCC: Area under the receiving operator characteristic curve; CRP: C-reactive protein; ED: Emergency Department; HBP: Heparin binding protein;
hsCRP: High sensitivity C-reactive protein; ICU: Intensive care unit; IQR: Interquartile range; PCT: Procalcitonin; PSP: Pancreatic stone protein; SAPS: Simplified acute physiology
score; sCD25: Soluble CD25; SIRS: Systemic inflammatory response syndrome; UTI: Urinary tract infection; VAP: Ventilator-associated pneumonia; WCC: White cell count; wGA:
Weeks of gestational age.
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Table 2. Summary of clinical evidences pancreatic stone protein for diagnosis of infection and sepsis (cont.).
Purpose of the study Study population, characteristics Results, main measurements Conclusion Ref.
PSP as a diagnostic marker for
infection and sepsis in ED
152 consecutive patients
admitted to ED (infection: 129,
including 47 with sepsis)
Accuracy (AUROCC) to predict:
Infection:
sCD25 = 0.87 (95% CI: 0.80–0.94),
PCT = 0.90 (95% CI: 0.85–0.96),
PSP = 0.84 (95% CI: 0.77–0.90);
Sepsis:
sCD25 = 0.84 (95% CI: 0.76–0.91),
PCT = 0.82 (95% CI: 0.74–0.90),
PSP = 0.87 (95% CI: 0.81–0.94)
PSP and soluble CD25 performed
well to detect infection and to
identify patients with sepsis in the
ED setting
[35]
PSP as marker of organ failure in
VAP and a prognostic marker for
mortality
101 patients with clinically
diagnosed VAP (sepsis, n = 25)
Accuracy (AUROCC) of:
PSP at day 0 to predict survival (cutoff:
24 ng/ml) = 0.69 (95% CI: 0.57–0.8);
PSP at day 7 to predict death (cutoff:
177 ng/ml) = 0.76 (95% CI: 0.62–0.91)
PSP reflects organ
dysfunction/failure and outcome in
VAP and allows stratifying patients
with good and poor outcome
[36]
PSP as an early biomarker
predicting mortality in sepsis
patients requiring ICU
management
107 patients with severe sepsis or
septic shock within 24 h of
admission in a medico-surgical
ICU
Accuracy (AUROCC) to:
– predict death in sepsis patients
CRP = 0.41,
PCT = 0.46,
PSP = 0.65;
– predict death in septic shock patients CRP
= 0.44,
PCT = 0.45,
PSP = 0.65
PSP measurement within 24 h of ICU
admission predicts risk of in-hospital
death more accurately than PCT and
CRP
[37]
PSP combined with severity
scores to predict mortality in
sepsis patients requiring ICU
management
149 patients with severe sepsis
(n = 93) or septic shock (n = 156)
Accuracy (AUROCC) to predict hospital
mortality:
SAPS II + log(PSP) = 0.66 (95% CI:
0.56–0.76),
SAPS II + CRP + log(PSP) = 0.68 (95% CI:
0.59–0.78),
SAPS II + CRP + log(PCT) + log(PSP) = 0.71
(95% CI: 0.62–0.80)
Initial PSP has a prognostic value in
patients with severe sepsis and septic
shock requiring ICU management. A
model combining severity scores
with PCT and PSP improves mortality
prediction in these patients
[38]
PSP in infants and children
PSP diagnostic values in early
onset neonatal sepsis
52 uninfected neonates,
52 infected neonates
Accuracy (AUROCC) for infection:
PSP (cutoff 13 ng/ml) = 0.87
CRP (cutoff 60 mg/ml) = 0.81
The high negative predictive value
of PSP (89.3%) indicates that the
serum PSP level is a good marker for
diagnosis of early onset neonatal
sepsis
[39]
PSP to predict neonatal sepsis 137 newborns, 34 wGA, 33 with
infection, 104 without infection
Accuracy (AUROCC) to predict sepsis:
PCT (cutoff: 2 ng/ml) = 0.77 (95% CI
0.66–0.87),
PSP (9 ng/ml) = 0.69 (95% CI: 0.59–0.80),
Combined = 0.83 (95% CI: 0.74–0.93)
The diagnostic performance of PSP
and PCT was superior to that of
traditional markers and a
combination of both improved the
diagnosis of sepsis
[40]
PSP as diagnostic marker of
sepsis-related organ failure in
children
62 children admitted in ICU,
14 SIRS (no infection),
3 sepsis,
17 severe sepsis,
28 septic shock
Diagnostic characteristics to predict sepsis
with organ failures:
Specificity = 0.92, Sensitivity = 0.50,
Positive predictive value = 0.87,
Negative predicative value = 0.65,
AUROCC = 0.70
PSP did not differ between patients
with systemic inflammatory response
syndrome and septic condition until
organ dysfunction signs were
present. Patients who died tended
to have higher PSP levels
[41]
PSP as prognostic factor (28 days
all-cause mortality) in children
with sepsis and septic shock (PSP
measurement within 24 h after
ICU admission)
214 children with sepsis, within
24h of admission
Accuracy (AUROCC) to predict death:
PSP = 0.83 (95% CI: 0.77–0.88),
PCT = 0.76 (95% CI: 0.70–0.82),
hsCRP = 0.73 (95% CI: 0.67–0.79),
Combined = 0.92 (95% CI: 0.87–0.95);
p  0.001
PCT, hsCRP and PSP levels predict
outcome. Combination of all three
biomarkers significantly improves
the prediction.
PSP is a promising biomarker of risk
and useful clinical tool for risk
stratification of pediatric sepsis
[42]
PSP diagnostic value for early
pediatric acute osteomyelitis
187 children:
80 healthy volunteers
95 nonacute osteomyelitis
92 acute osteomyelitis
Accuracy (AUROCC) for diagnosis of acute
osteomyelitis:
PSP = 0.796 (95% CI: 0.731–0.851)
(cutoff = 26.5 ng/ml =
PCT = 0.767 [95% CI: 0.700–0.826] [cutoff]
3.56 ng/ml)
PSP + PCT = 0.903 (95% CI: 0.851–0.941)
PSP and PCT are promising
biomarker for early diagnosis of
pediatric acute osteomyelitis. PSP
was found to have a slightly superior
AUROCC, while the combination of
PSP and PCT resulted in substantially
high diagnostic performances
[43]
This table summarized the key clinical findings of studies in which the PSP has been evaluated for different clinical situations on different patient populations. For most studies, PSP
has been compared with other standard or emerging biomarkers.
AUC: Area under the curve; AUROCC: Area under the receiving operator characteristic curve; CRP: C-reactive protein; ED: Emergency Department; HBP: Heparin binding protein;
hsCRP: High sensitivity C-reactive protein; ICU: Intensive care unit; IQR: Interquartile range; PCT: Procalcitonin; PSP: Pancreatic stone protein; SAPS: Simplified acute physiology
score; sCD25: Soluble CD25; SIRS: Systemic inflammatory response syndrome; UTI: Urinary tract infection; VAP: Ventilator-associated pneumonia; WCC: White cell count; wGA:
Weeks of gestational age.
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PCT, IL-6 and other cytokines for the diagnosis of sepsis and prognosis of unfavorable outcome. In all these studies,
PSP levels well correlated with disease severity, ranging from <20 ng/ml in adult patients without infection to
several hundred nanogram/milliliter in patients with severe sepsis and even several thousand nanograms/milliliters
in the case of septic shock (Table 2).
A unique characteristic of PSP is that it may start to increase above the normal level range before the development
of clinical signs and symptoms of sepsis. In a pivotal study, serial PSP measurements in multiple trauma patients
were able to identify patients who were developing a sepsis before the rise of other biomarkers, and before the clinical
diagnostic, in most cases [29]. The same has been reported in patients after cardiac surgery. In all 120 patients PSP
levels raised after elective cardiac surgery, independently from the characteristics of surgery, but was significantly
higher postoperatively, at 24, 48 and 72 h among the 18 patients (15%) developing an infectious complication [34].
In a population of patients with sepsis-related complications, PSP levels have demonstrated a high diagnostic
accuracy to discriminate the severity of peritonitis and to predict death in the ICU [33]. In another study, PSP
levels reflected organ dysfunction and predicted death in ventilator-associated pneumonia (VAP), which allowed
stratifying patients with good and poor outcome [36]. The value of PSP to predict in-hospital mortality in patients
with severe sepsis and septic shock requiring ICU management has been further demonstrated by Que et al. [37], who
also highlighted in another research that a model combining severity scores with PCT and PSP improves mortality
prediction in these patients [38]. The clinical accuracy of PSP to identify sepsis and multiple organ dysfunction was
also confirmed in a cohort of unselected, heterogeneous patients admitted to intensive or high-dependency care
unit [32], as well as on a cohort of patients presenting to ED with suspicion of infection [35].
Data on the diagnostic performance of PSP for sepsis are also available for children and neonates. In children,
the combination of PSP, PCT and CRP was superior to each of the individual markers for the risk stratification
of pediatric sepsis [42], and the combination of PSP and PCT had significantly higher diagnostic accuracy for
osteomyelitis than that of PSP or PCT alone [43]. In neonates, a population particularly at risk of sepsis and
associated with high morbidity and mortality, a high negative predictive value of PSP, alone or in combination with
PCT was found for early onset neonatal sepsis, which supports the concept of using PSP to rule out sepsis and
thereby safely reduce antibiotic treatment in this specific population [39,40].
Potential use of PSP in clinical diagnosis & management of sepsis & the need for short
turnaround time
The potential for the use of PSP alone or in combination with other sepsis biomarkers, especially CRP and PCT,
is promising. The higher accuracy of PSP in the diagnosis of sepsis, its good correlation with the severity of organ
failures and its unique prognostic value strongly argue for its use in the clinical setting (Table 2).
• PSP may be used to confirm the early suspicion of sepsis. PSP may thus allow reducing poorly justified ‘emotional
prescriptions’ of antibiotic, a major goal of antibiotic stewardship programs;
• PSP may be used to stratify patients early according to disease severity, alone or in combination with routine
severity scores such as APACHE II, SAPS II and SOFA;
• PSP may be used to stratify patients early according to prognosis and outcome, and thus allow correct triage and
further management;
• PSP may ease screening and inclusion of septic patients in clinical trials.
Diagnosis of sepsis is especially challenging as the clinical signs and symptoms are not specific; most of the time a
large overlap exists with noninfective causes of systemic inflammation. As early treatment of sepsis is associated with
improved outcomes, rapid identification is key – every hour of delayed treatment represents increasing mortality [44].
High suspicion based on markers immediately available to the clinicians, such as body temperature, heart and
respiratory rates, acute alteration of mental function and low blood pressures are neither sufficiently specific nor
sensitive enough, even if used in combination as part of a clinical score [45]. Therefore, these scoring systems should
be complemented with other parameters to improve their prognostic and/or diagnostic performances. In respect
to that, blood host protein biomarkers represent certainly a promising approach, if (and only if ) available within
minutes to the clinicians.
Availability of PSP results within minutes from a drop of whole blood may bring a real breakthrough in the
management of patients with sepsis or at risk of developing a sepsis. POCT has made tremendous progress in recent
years and is today already commonly used for several applications in ED and ICU, such as for the bedside serial
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Adhesion layer Patient analyte (if present)
Fluorescently-labeled detecting antibody
Other sample proteins
Hundreds
of nanometers
Capture molecule
Non-fouling molecule
Flow direction
Laser
Figure 1. Lateral schematic view of a nanochannel; the high surface-to-volume ratio enhances capture of analyte to the solid phase.
Sample is mixed with a detecting reagent and deposited at the entrance of a nanofluidic biosensors. The concentration of analyte is
proportional to the fluorescence emitted by the detecting antibody label with a fluorophore.
Reproduced with permission from [46] C© Springer Nature (2018).
measurement of blood gas, lactate, electrolytes or glucose. Implementing a novel POCT in these clinical settings
is challenging (extensive training must be conducted to ensure good practices; quality controls are performed
outside the clinical laboratory; test results must be incorporated to the hospital information system; POCT are
more expensive than corresponding tests on large laboratory analyzers. . . ). Therefore, advantages of using a POCT
must counterbalance these limitations. This can be achieved through both proven clinical benefit of using a POCT
and an economical benefit taking into consideration the entire patient stay. POCT has also an added advantage in
settings where clinical laboratories cannot deliver results in the time consensually defined with clinicians, or when
closed at night or weekends. New technologies are today requiring few or no preanalytical activities (to shorten
hand-on time and mitigate risk of exposure of the operator to potentially biohazardous material), and have analytic
performances meeting clinician’s needs (in particular regarding accuracy, precision, analytical sensitivity and assay
reportable range).
A recent technology based on nanofluidics (abioSCOPE, Abionic SA, Epalinges, Switzerland) allows quanti-
fying proteins at the picomolar range from a drop of whole blood in a few minutes and without preanalytic
work. Nanofluidic channels strongly influence the diffusional behavior of biomolecules and increase molecular
interactions [43]. Due to the submicron structuration, the binding surface for the capture biomolecule is strongly
increased, which enhances the sensitivity of the sensor and the biomolecular interaction leading to reduced assay
times (Figure 1).
This technology has been used to develop a rapid PSP test, which is currently evaluated in ICU for the earlier
detection of sepsis and represents an interesting solution as it combines two key requirements: short total turnaround
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time and a biomarker with high sensitivity and specificity to aid in identifying sepsis. As PSP is a biomarker giving
information on urgent situations, future studies using PSP must be conducted at the bedside to clearly assess the
benefit of obtaining PSP results within minutes for the management of sepsis patients and patients at risk of sepsis.
Conclusion
With an aging population worldwide, increasing prevalence of noncommunicable, chronic or serious illnesses
associated with higher risk of sepsis (i.e., diabetes, obesity, malignancy. . . ) and the threat of global antimicrobial
resistances, sepsis incidences are unlikely to diminish in the near future. However, on the longer term, the
combination of rapid diagnostic solutions, biomarker-guided therapies and an increased awareness of sepsis in both
the community and among clinicians will contribute to reduce death and long-term complications of sepsis. The
promising results obtained so far with the PSP in various clinical situations support that this biomarker has the
potential to contribute to a better management of sepsis.
Future perspective
Despite an improved understanding of the pathophysiology of sepsis, a worldwide recognized need of earlier
detection and the clinical evaluation of hundreds of proteins, metabolites, host and pathogen genetic markers,
diagnosis and prognosis of sepsis remains a daily challenge for clinicians. Recent technological advancements and
the discovery of novel promising markers open new avenues for the development of fast diagnostic solutions at the
bedside, using measurements of biomarkers with high diagnostic accuracy for infection, sepsis and septic shock.
The agenda for further evaluation of the clinical utility of PSP should at least focus on:
• Demonstrating the impact of using PSP for: the early identification of sepsis in the ICU before the onset of
typical signs and symptoms of sepsis; the prompt confirmation of sepsis in patients with clinical suspicion of
infection (ICU, ED, out-patient clinic, nursing homes, ambulances. . . ); and the risk stratification of septic
patients and prognostication of their outcome to facilitate triage decision;
• Confirming the feasibility, clinical impact and economic benefit of serial real-time measurements of PSP in
various settings, such as ICU and ED, using POCT technology (versus measurement in clinical laboratories);
• Bringing robust evidence, through large randomized trials, that bedside measurement of PSP in ED or in ICU is
changing clinicians’ behavior; thereby improving patient health outcome and potentially, adherence to antibiotic
stewardship programs without jeopardizing patient safety;
• Finally, better understanding the molecular mechanisms of PSP function, in both healthy and septic patients,
including a thorough understanding of the PSP kinetics (peak maximum level in presence of infection and/or
sepsis and clearance upon resolution of the infection and/or organ dysfunction) and identification of medical
conditions resulting in a rise of the PSP level independently of the presence of an infection or sepsis.
In addition, there are a couple of questions that need to be answered to clearly capture the potential of PSP
compared with currently available biomarkers: how is PSP level evolving in patients with viral, fungal, parasitic,
gram positive and negative bacteria? Is the PSP a reliable biomarker in neutropenic septic patients? What is the
clinical utility of PSP for the identification of early onset neonatal sepsis, in particular in preterm babies? Are there
any conditions leading to a rise of PSP levels that are not related to infection? As PSP is secreted mostly by the
pancreas, could it be a marker of severity for pancreatitis? What is, if any, the clinical impact of combining PSP with
other biomarkers? Would the combination of PSP with other established or new biomarkers and/or with scoring
systems increase diagnostic accuracy of sepsis?
The first 5 years should allow finding answers to these specific open questions. Once the clinical utility of PSP
has been confirmed within large studies, the five following years should push the PSP use outside the EDs and
ICUs to more diverse patient populations and clinical situations. This is the only way to make PSP part of the
standard of care.
In parallel, our better understanding of the pathophysiology of PSP in sepsis will probably allow better sorting
septic patients, which may in turn improve management by selecting the intervention that suits most the patient
condition.
Beside clinical research and clinical utility, the health economic benefit of measuring PSP at the point-of-care
in different clinical scenario and patient populations must also be demonstrated to facilitate technology appraisal
processes by national regulatory agencies.
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Executive summary
• Sepsis is a global health problem worldwide, and its diagnosis is today still challenging. Current blood
biomarkers, used to help clinicians diagnosing sepsis, are neither enough sensitive nor specific.
• Pancreatic stone protein (PSP) is a protein secreted by the pancreas and its response to stress induced by systemic
infection and sepsis.
• Several clinical studies performed in intensive care units and in Emergency Department have shown great
potential of PSP measurement for early identification of sepsis and prediction of disease outcome. In those
studies, PSP was systematically performing similarly or better than procalcitonin and C-reactive protein.
• More clinical data and a better understanding of the pathophysiological mechanisms of PSP function are needed
to assess the potential of PSP as a disruptive biomarker for the early diagnosis of sepsis, in adults, children and
neonates.
• As sepsis is a condition that demands an urgent intervention to increase chances of favorable outcome, rapid
measurement at the bedside of PSP is an interesting approach to improve identification and management of
septic patients.
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